Irinotecan plus carboplatin for patients with carcinoma of unknown primary site

British Journal of Cancer

Volumn 100, Issue 1, 2009, Pages 50-55

  Yonemori, K ^a   Ando, M ^a   Yunokawa, M ^a   Hirata, T ^a   Kouno, T ^a   Shimizu, C ^a   Tamura, K ^a   Katsumata, N ^a   Hirakawa, A ^b   Matsumoto, K ^a,c   Yamanaka, Y ^a,d   Arioka, H ^e   Fujiwara, Y ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b TOKYO UNIVERSITY OF SCIENCE   (Japan)

^c HYOGO CANCER CENTER   (Japan)

^d TOCHIGI CANCER CENTER   (Japan)

^e YOKOHAMA ROSAI HOSPITAL   (Japan)

Author keywords

Carboplatin; Chemotherapy; Irinotecan; Unknown primary

Indexed keywords

CARBOPLATIN; IRINOTECAN; TUMOR MARKER;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BLOOD TRANSFUSION; CANCER GROWTH; CANCER LOCALIZATION; CANCER OF UNKNOWN PRIMARY SITE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEART PALPITATION; HUMAN; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARBOPLATIN; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, UNKNOWN PRIMARY; SURVIVAL RATE;

EID: 58149265020     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604829     Document Type: Article

References (42)

1. Balaña C, Manzano JL, Moreno I, Cirauqui B, Abad A, Font A, Mate JL, Rosell R (2003) A phase II study of cisplatin, etoposide and gemcitabine in an unfavourable group of patients with carcinoma of unknown primary site. Ann Oncol 4: 1425-1429
2. Briasoulis E, Fountzilas G, Bamias A, Dimopoulis MA, Xiros N, Aravantinos G, Samantas E, Kalofonos H, Makatsoris T, Mylonakis N, Papakostas P, Skarlos D, Varthalitis I, Pavlidis N (2008a) Multicenter phase II trial of irinotecan plus oxaliplatin in patients with poor-prognosis cancer of unknown primary: a Hellenic cooperative oncology group study. Cancer Chemother Pharmacol 62: 277-284
3. Briasoulis E, Kalofonos H, Bafaloukos D, Samantas E, Fountzilas G, Xiros N, Skarlos D, Christodoulou C, Kosmidis P, Pavlidis N (2000) Carboplatin plus paclitaxel in unknown primary carcinoma; a phase II Hellenic Cooperative Oncology Group Study. J Clin Oncol 18: 3101-3107
4. Briasoulis E, Pavlidis N, Felip E (2008b) Cancers of unknown primary site: ESMO clinical recommendation for diagnosis, treatment and follow-up. Ann Oncol 19(Suppl 2): ii106-ii107
5. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7: 1748-1756
6. Cockcroft DW, Gault MH (1976) Prediction of creatine clearance from serum creatinine. Nephron 16: 31-41
7. Culine S, Fabbro M, Ychou M, Romieu G, Cupissol D, Pinguet F (2002b) Alternative bimonthly cycles of doxorubicin, cyclophosphamide, and etoposide, cisplatin with hematopoietic growth factor support in patients with carcinoma of unknown primary site. Cancer 94: 840-846
8. Culine S, Kramar A, Saghatchian M, Bugat R, Lesimple T, Lortholary A, Merrouche Y, Laplanche A, Fizazi K (2002a) Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol 20: 4679-4683
9. Culine S, Lortholary A, Voigt JJ, Bugat R, Théodore C, Priou F, Kaminsky MC, Lesimple T, Pivot X, Coudert B, Douillard JY, Merrouche Y, Allouache J, Goupil A, Négrier S, Viala J, Petrow P, Bouzy J, Laplanche A, Fizazi K (2003) Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study-trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). J Clin Oncol 21: 3479-3482
10. Dowell JE, Garrett AM, Shyr Y, Johonson DH, Hande KR (2001) A randomized phase Ii trial in patients with carcinoma of an unknown primary site. Cancer 91: 592-597
11. El-Rayes BF, Shields AF, Zalupski M, Heilbrun LK, Jain V, Terry D, Ferris AM, Philip PA (2005) A phase II study of carboplatin and paclitaxel in adenocarcinoma of unknown primary. Am J Clin Oncol 28: 152-156
12. Greco FA, Burris III HA, Erland JB, Gray JR, Kalman LA, Schreeder MT, Hainsworth JD (2000b) Carcinoma of unknown primary site. Cancer 89: 2655-2660
13. Greco FA, Burris III HA, Litchy S, Barton JH, Bradof JE, Richards P, Scullin Jr DC, Erland JB, Morrissey LH, Hainsworth JD (2002) Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network study. J Clin Oncol 20: 1651-1656
14. Greco FA, Burris III HA, Spigel DR, Thompson DS, Waterhouse DM, Hanson S, Vazquez ER, Hainsworth JD (2008) Paclitaxel/carboplatin plus bevacizumab/erlotinib as first-line treatment for patients with carcinoma of unknown primary site. J Clin Oncol 26(15S): 239s
15. Greco FA, Erland JB, Morrissey LH, Burris III HA, Hermann RC, Steis R, Thompson D, Gray J, Hainsworth JD (2000a) Carcinoma of unknown primary site: phase II trials with docetaxel plus cisplatin or carboplatin. Ann Oncol 11: 211-215
16. Greco FA, Hainsworth JD (2008) Cancer of unknown primary site. In Cancer, Principle and Practice of Oncology, De Vita VT, Lawrence TS, Rosenberg SA (eds), pp 2363-2387. Lippincott Williams and Wilkins: Philadelphia
17. Greco FA, Rodriguez GI, Shaffer DW, Hermann R, Litchy S, Yardley DA, Burris III HA, Morrissey LH, Erland JB, Hainsworth JD (2004) Carcinoma of unknown primary site: sequential treatment with paclitaxel/carboplatin/etoposide and gemcitabine/irinotecan: a Minnie Pearl Cancer Research Network II phase trial. Oncologist 9: 644-652
18. Gross-Goupil M, Fourcade A, Blot A, Penel N, Negrier S, Culine S, Moerrouche Y, Bouzy J, Laplanche A, Fizazi K (2008) A randomized trial of cisplatin with or without gemcitabine in patients with carcinoma of an unknown primary and without poor prognostic factors: results of the GEFCAPI02 trial. Ann Oncol 19(Suppl 8): vii248
19. Guardiola E, Pivot X, Tchicknavorian X, Magne N, Otto J, Thyss A, Schnider M (2001) Combination of cisplatin-doxorubicin-cyclophosphamide in adenocarcinoma of unknown primary site: a phase II trial. Am J Clin Oncol 24: 372-375
20. Hainsworth JD, Burris III HA, Calvert SW, Willcutt NT, Scullin Jr DC, Bramham J, Greco FA (2001) Gemcitabine in the second-line therapy of patients with carcinoma of unknown primary site: a II phase trial of the Minnie pearl cancer research network. Cancer Invest 19: 335-339
21. Hainsworth JD, Spigel DR, Farley C, Thompson DS, Shipley DL, Greco FA (2007) Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie pearl cancer research network. J Clin Oncol 25: 1747-1752
22. Hainsworth JD, Spigel DR, Raefsky EL, Kuzur ME, Yost K, Kommor M, Litchy S, Greco FA (2005) Combination chemotherapy with gemcitabine and irinotecan in patients with previously treated carcinoma of unknown primary site: a Minnie pearl cancer research network phase II trial. Cancer 104: 1992-1997
23. Kano Y, Akutsu M, Suzuki K, Yoshida M (1993) Effects of carboplatin in combination with other anticancer agents on human leukemia cell lines. Leukemia Res 17: 113-119
24. Kano Y, Suzuki K, Akutsu M, Suda K, Inoue Y, Yoshida M, Sakamoto S, Miura Y (1992) Effects of CPT-11 in combination with other anticancer agents in culture. Int J Cancer 50: 604-610
25. Macdonald AG, Nicolson MC, Samuel LM, Hutcheon AW, Ahmed FY (2002) A phase II study of mitomycin C, cisplatin and continuous infusion 5-Fluorouracil in the treatment of patients with carcinoma of unknown primary site. Br J Cancer 86: 1238-1248
26. Massard C, Voigt JJ, Laplanche A, Culine S, Lortholary A, Bugat R, Theodore C, Priou F, Kaminsky MC, Lesimple T, Pivot X, Coudert B, Douillard JY, Merrouche Y, Fizazi K (2007) Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy? Br J Cancer 97: 857-861
27. Misawa T, Kikkawa F, Maeda O, Obata NH, Higashide K, Suganuma N, Tomoda Y (1995) Establishment and characterization of acquired resistance to platinum anticancer drugs in human ovarian carcinoma cells. Jpn J Cancer Res 86: 88-94
28. Mukai H, Watanabe T, Ando M, Katsumata N (2003) Unknown primary carcinoma: a feasibility assessment of combination chemotherapy with cisplatin and docetaxel. Int J Clin Oncol 8: 23-25
29. Palmeri S, Lorusso V, Palmeri L, Vaglica M, Porta C, Nortilli R, Ferraú F, Comella G, Massidda B, Danova M (2006) Cisplatin and gemcitabine with either vinorelbine or paclitaxel in the treatment of carcinomas of unknown primary site : results of an Italian multicenter, randomized, phase II study. Cancer 107: 2898-2905
30. Park YH, Ryoo BY, Choi SJ, Yang SH, Kim HT (2004) A phase II study of paclitaxel plus cisplatin chemotherapy in an unfavourable group of patients with cancer of unknown primary site. Jpn J Clin Oncol 34: 681-685
31. Parnis FX, Olver IN, Kotasek D, Norman J, Taylor A, Russell J, Patterson K, Keefe D, Marafioti T (2000) Phase II study of epirubicin, cisplatin and continuous infusion 5-fluorouracil for carcinoma of unknown primary site. Ann Oncol 11: 883-884
32. Pavlidis N, Briasoulis E, Hainsworth J, Greco FA (2003) Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 39: 1990-2005
33. Pentheroudakis G, Briasoulis E, Kalofonos HP, Fountzilas G, Economopoulos T, Samelis G, Koutras A, Karina M, Xiros N, Samantas E, Bamias A, Pavlidis N (2008) Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: a multicenter Hellenic cooperative oncology group phase II study. Acta Oncologica 47: 1148-1155
34. Piga A, Nortilli R, Cetto GL, Cardarelli N, Luzi Fedeli S, Fiorentini G, D'Aprile M, Giorgi F, Parziale AP, Contu A, Montironi R, Gesuita R, Carle F, Cellerino R (2004) Carboplatin, doxorubicin and etoposide in the treatment of tumours of unknown primary site. Br J Cancer 90: 1898-1904
35. Pittman KB, Olver IN, Koczwara B, Kotasek D, Patterson WK, Keefe DM, Karapetis CS, Parnis FX, Moldovan S, Yeend SJ, Price TJ (2006) Gemcitabine and carboplatin in carcinoma of unknown primary site: a phase 2 Adelaide Cancer Trials and Education Collaborative study. Br J Cancer 95: 1309-1313
36. Saghatchian M, Fizazi K, Borel C, Ducreux M, Ruffie P, Le Chevalier T, Theodore C (2001) Carcinoma of an unknown primary site: a chemotherapy strategy based on histological diffentiation - results of a prospective study. Ann Oncol 12: 535-540
37. Schneider BJ, El-Rayes B, Muler JH, Philip PA, Kalemkerian GP, Griffith KA, Zalupski MM (2007) Phase II trial of carboplatin, gemcitabine, and capecitabine in patients with carcinoma of unknown primary site. Cancer 110: 770-775
38. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216
39. van der Gaast A, Verweij J, Planting AS, Hop WC, Stoter G (1996) Simple prognostic model to predict survival in patients with undifferentiated carcinoma of unknown primary site. J Clin Oncol 13: 1720-1725
40. Voog E, Merrouche Y, Trillet-Lenoir V, Lasset C, Peaud PY, Rebattu P, Negrier S (2000) Multicentric phase II study of cisplatin and etoposide in patients with metastatic carcinoma of unknown primary. Am J Clin Oncol 23: 614-616
41. Yakushiji S, Ando M, Yonemori K, Kohno T, Shimizu C, Katsumata N, Fujiwara Y (2006) Cancer of unknown primary site: review of consecutive cases at the National Cancer Center Hospital of Japan. Int J Clin Oncol 11: 421-425
42. Yonemori K, Katsumata N, Yamamoto N, Kasamatsu T, Yamada T, Tsunematsu R, Fujiwara Y (2005) A phase I study and pharmacologic evaluation of irinotecan and carboplatin for patients with advanced ovarian carcinoma who previously received platinum-containing chemotherapy. Cancer 104: 1204-1212